JAGX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	42.90M
Average Volume	60.18M
Market Cap	49.72M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0.00100 (0.56%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Chaturvedi Pravin R	Buy	134	Common Stock
2024-04-05	Chaturvedi Pravin R	Sell	134	Restricted stock units
2024-04-05	Wolin Jonathan S.	Buy	89	Common Stock
2024-04-05	Wolin Jonathan S.	Sell	89	Restricted stock units
2024-04-05	Lizak Carol R.	Buy	60	Common Stock

INSIDER POWER
80.43
Last 99 transactions
Buy: 3 516 210 \| Sell: 493 473

Volume Correlation

Long: -0.40 (neutral)

Short: 0.50 (weak)

Signal:(46.758) Neutral

Jaguar Health Inc Correlation

10 Most Positive Correlations
EVLO	0.972
YJ	0.968
RPTX	0.967
CLFD	0.966
CFRX	0.963
CYTO	0.96
GSMG	0.959
REYN	0.959
GXGX	0.959
BHTG	0.957

10 Most Negative Correlations
IVCP	-0.983
MSDA	-0.982
VLAT	-0.982
HERA	-0.982
FICV	-0.982
PRLH	-0.981
ACQR	-0.98
CRZN	-0.98
AGGR	-0.979
CREC	-0.979

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Jaguar Health Inc Correlation - Currency/Commodity

0.00
( neutral )

Jaguar Health Inc Financials

Annual	2023
Revenue:	$9.76M
Gross Profit:	$5.34M (54.67 %)
EPS:	$-1.790

FY	2023
Revenue:	$9.76M
Gross Profit:	$5.34M (54.67 %)
EPS:	$-1.790

FY	2022
Revenue:	$11.96M
Gross Profit:	$9.94M (83.11 %)
EPS:	$-36.18

FY	2021
Revenue:	$4.34M
Gross Profit:	$2.00M (46.18 %)
EPS:	$-294.27

Financial Reports:

No articles found.

Jaguar Health Inc

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.